Theriva Biologics (NYSEAMERICAN:TOVX) Issues Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) posted its earnings results on Tuesday. The company reported ($6.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.25) by ($0.56), Zacks reports.

Theriva Biologics Price Performance

Shares of Theriva Biologics stock traded down $0.03 during mid-day trading on Wednesday, reaching $1.41. 158,027 shares of the stock traded hands, compared to its average volume of 1,006,092. Theriva Biologics has a fifty-two week low of $1.24 and a fifty-two week high of $17.11. The stock has a market capitalization of $3.19 million, a P/E ratio of -0.04 and a beta of 1.34.

Wall Street Analysts Forecast Growth

Separately, Maxim Group decreased their target price on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.